Anteris获美敦力战略投资 3.2亿美元融资持续推进TAVR技术研发

美股速递
Jan 23

Anteris Technologies Global(NASDAQ升级/双重上市)宣布获得医疗科技巨头美敦力公司的战略投资。此次融资属于总额达3.2亿美元的资本募集计划的重要组成部分,所筹资金将专项用于加速经导管主动脉瓣置换术(TAVR)技术的创新研发进程。

该战略合作将整合Anteris在生物材料领域的突破性技术与美敦力全球领先的临床商业化能力。通过本轮融资,Anteris计划扩大其独家ADAPT®生物材料技术在结构性心脏病领域的应用范围,同时推进第二代TAVR产品线的临床试验。此次资本运作凸显了医疗科技巨头对新一代心脏瓣膜技术赛道的前瞻性布局。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10